In an older woman with low anti‑Müllerian hormone (AMH) indicating poor ovarian reserve, which ovarian stimulation protocol—Pergoveris (recombinant FSH + LH), Gonal‑F (recombinant FSH) plus Rekovelle (recombinant LH), Menopur (human menopausal gonadotropin), or Humog (human menopausal gonadotropin)—is optimal?

Optimal Ovarian Stimulation for Older Women with Low AMH

For older women with low AMH (diminished ovarian reserve), use recombinant FSH plus recombinant LH (Pergoveris) or human menopausal gonadotropin (Menopur/Humog) within a GnRH antagonist protocol, starting with 225 IU daily dosing. Both approaches provide comparable outcomes, though emerging evidence suggests potential advantages with LH supplementation in this specific population 1.

Medication Selection Strategy

First-Line Options (Equivalent Efficacy)

Option 1: Pergoveris (r-FSH/r-LH 2:1 ratio)

• Most recent evidence from 2026 shows improved follicular efficiency in POSEIDON groups 3-4 (AMH <1.2 ng/mL) 2
• Higher follicular output rate (59.4% vs 52.8%) and follicle-to-oocyte index (82.6% vs 70.9%)
• Significantly higher ongoing pregnancy rates (30.4% vs 15.5% per transfer) in fresh cycles
• Fewer cycle cancellations before retrieval (1.1% vs 10.1%)
• Faster embryo morphokinetics with earlier blastulation timing 3

Option 2: Menopur or Humog (hMG products)

• FDA-approved starting dose: 225 IU daily beginning cycle day 2-3 1
• Contains both FSH and LH activity from urinary source
• 2026 data shows equivalent live birth rates compared to r-FSH+r-LH in poor responders 4
• Maximum daily dose should not exceed 450 IU
• Treatment duration should not exceed 20 days

Alternative Approaches

Gonal-F (r-FSH alone) + separate LH supplementation

• Can combine Gonal-F with Rekovelle (r-LH) to achieve similar FSH:LH ratios as Pergoveris
• However, a 2015 RCT in women ≥35 years showed no difference in live birth rates between r-FSH/r-LH versus r-FSH alone (16.7% vs 17.5%) 5
• This contradicts more recent 2026 data showing benefits of LH supplementation 2

Rekovelle alone is NOT recommended - this is an FSH product requiring individualized dosing based on AMH/weight and lacks the LH component critical for this population.

Protocol Framework

Dosing Algorithm

1. Baseline assessment: Verify AMH <1.2 ng/mL, exclude pregnancy, assess male partner fertility 1

2. Starting dose:

   • Pergoveris: 150/75 IU daily (or higher based on reserve)
   • Menopur: 225 IU daily
   • Can combine with additional FSH if needed (total ≤450 IU/day) 1

3. GnRH antagonist addition: Start on day 5 of stimulation 5

4. Dose adjustments:

   • First adjustment after 5 days based on ultrasound and estradiol
   • Subsequent adjustments no more frequently than every 2 days
   • Maximum increment: 150 IU per adjustment 1

5. Trigger timing: When adequate follicular development achieved, withhold hCG if OHSS risk evident 1

Critical Evidence Considerations

Strength of LH Supplementation Evidence

The evidence for LH supplementation shows conflicting results:

• The 2015 RCT 5 found no benefit (but was likely underpowered)
• The 2026 retrospective cohort 2 shows substantial benefits with LH priming protocol
• The 2026 comparative study 4 shows equivalence between r-FSH+r-LH and r-FSH+hMG

The most recent 2026 data 2 represents the highest-quality evidence specific to your population (POSEIDON 3-4, AMH <1.2), showing odds ratio 2.20-2.41 for ongoing pregnancy with LH priming after adjusting for age, BMI, and AMH.

Why Not Gonal-F Alone?

While Gonal-F monotherapy is FDA-approved and widely used, in older women with low AMH, the theoretical benefit of LH activity (either from r-LH or hMG) addresses the physiologic LH deficiency that may occur with GnRH suppression. The 2026 morphokinetic data 3 suggests improved embryo quality parameters with combined FSH/LH stimulation.

Common Pitfalls to Avoid

• Do not exceed 450 IU total daily gonadotropin dose - increases OHSS risk without improving outcomes 1
• Do not extend treatment beyond 20 days - diminishing returns with prolonged stimulation 1
• Monitor closely for OHSS - withhold hCG trigger if >30 follicles or estradiol levels suggest high risk 1
• Verify negative pregnancy test before starting - these medications are contraindicated in pregnancy 6
• Do not use in women with high baseline FSH indicating primary ovarian failure 1

Bottom Line Algorithm

1. Choose either Pergoveris OR Menopur/Humog (both provide FSH+LH activity)
2. Start 225 IU daily on cycle day 2-3
3. Add GnRH antagonist on stimulation day 5
4. Adjust dose after 5 days based on response
5. Trigger when ready, avoiding OHSS risk

The 2026 evidence favors protocols incorporating LH activity from the start, with Pergoveris showing the most robust recent data in your specific population 2.